These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 20465362)
1. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Schultze A; Fiedler W Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362 [TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase: a potential target in cancer therapy. van Nimwegen MJ; van de Water B Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283 [TBL] [Abstract][Full Text] [Related]
5. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478 [TBL] [Abstract][Full Text] [Related]
6. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065 [TBL] [Abstract][Full Text] [Related]
7. FAK expression regulation and therapeutic potential. Li S; Hua ZC Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942 [TBL] [Abstract][Full Text] [Related]
8. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Gagne P; Akalu A; Brooks PC Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663 [TBL] [Abstract][Full Text] [Related]
9. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Head M; Jameson MB Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875 [TBL] [Abstract][Full Text] [Related]
11. Signal transduction by focal adhesion kinase in cancer. Zhao J; Guan JL Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797 [TBL] [Abstract][Full Text] [Related]
12. Antivascular agents for non-small-cell lung cancer: current status and future directions. Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762 [TBL] [Abstract][Full Text] [Related]
13. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625 [TBL] [Abstract][Full Text] [Related]
17. The interaction of radiation therapy and antiangiogenic therapy. O'Reilly MS Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126 [TBL] [Abstract][Full Text] [Related]